Completed PHASE2 INTERVENTIONAL 2-arm NCT00291720

Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

Sponsor: British Heart Foundation

Conditions Cardiovascular Disease Chronic Kidney Disease

Updated 5 times since 2017 Last updated: May 20, 2008 Started: Apr 30, 2005 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cardiovascular Disease and Chronic Kidney Disease and is currently completed. British Heart Foundation leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

British Heart Foundation
University Hospital Birmingham

Data source: University Hospital Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United Kingdom